An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton Classification Type IIIv, IV and V).

Trial Profile

An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton Classification Type IIIv, IV and V).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2017

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Alopecia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Jun 2010 Results published in the Journal of the American Academy of Dermatology.
    • 05 May 2009 Actual number of patients added as 153 as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Dec 2006 to Jan 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top